The global clinical microbiology market size was estimated at USD 4.57 billion in 2023 and is projected to reach USD 6.60 billion by 2030, growing at a CAGR of 5.35% from 2024 to 2030. This growth is primarily driven by the rising demand for laboratory services capable of detecting pathogen-based diseases, along with the increasing need for effective control measures to prevent the spread of infectious illnesses.

The market outlook is further strengthened by the expanding geriatric population, which is more susceptible to infections, and by the continual increase in targeted disease conditions requiring diagnostic evaluation. For instance, according to a WHO fact sheet published in April 2023, approximately 10.6 million people were diagnosed with tuberculosis globally in 2021, while 1.6 million individuals lost their lives to the disease. Such high disease burden highlights the growing need for advanced clinical microbiology solutions.

During the COVID-19 pandemic, the urgency for rapid and accurate testing significantly accelerated the development and adoption of innovative diagnostic technologies. Techniques such as Reverse Transcription-Polymerase Chain Reaction (RT-PCR), Loop-Mediated Isothermal Amplification (LAMP), and CRISPR-based assays became particularly prominent due to their high accuracy and faster turnaround times. Additionally, rapid antigen tests—including Abbott BinaxNOW and Quidel Sofia SARS antigen tests—received Emergency Use Authorization (EUA) from regulatory agencies and were widely deployed for large-scale screening, further advancing overall market growth.

Technological advancements that enable faster, more precise, and more reliable diagnosis continue to be key drivers of consumer demand for clinical microbiology testing. Modern automated microbial identification and susceptibility testing systems provide significantly improved performance compared to traditional manual methods. These advanced platforms use technologies such as mass spectrometry and molecular diagnostics to deliver quick and accurate results.

For example, bioMérieux’s VITEK MS system is a mass spectrometry-based automated platform capable of identifying a wide range of bacteria within minutes. Similarly, the BD Phoenix Automated Microbiology System can completely automate both microbial identification and antibiotic susceptibility testing, offering rapid and highly accurate diagnostic outcomes. Such innovations are transforming clinical microbiology workflows and contributing to the steady expansion of the market.

Key Market Trends & Insights:

• North America dominated the market and accounted for a revenue share of 39.28% in 2023. This strong regional presence can be attributed to well-established healthcare infrastructure, widespread adoption of advanced diagnostic technologies, and high awareness regarding infectious disease management. In addition, continuous investments in clinical laboratories and ongoing research initiatives contribute significantly to the region’s leadership position.

• The clinical microbiology market in the U.S. is expected to grow over the forecast period, driven by increasing testing volumes, rising prevalence of infectious diseases, and expanding utilization of molecular diagnostic tools. Moreover, supportive government policies, along with the presence of major industry players, are anticipated to further strengthen the market’s growth trajectory in the country.

• By product, the reagents segment dominated the market with a share of 72.20% in 2023. The dominance of this segment is primarily due to the recurring demand for consumables in microbiological testing processes. Frequent testing in clinical laboratories requires continuous replenishment of reagents, thereby ensuring steady market demand. Additionally, advancements in assay formulations and increasing use of specialized reagents for high-precision tests further contribute to this segment’s large share.

• By disease, the respiratory diseases segment dominated the market in 2023. The substantial share of this segment can be linked to the high global incidence of respiratory infections and the increasing need for rapid and accurate diagnostic solutions. Outbreaks of viral and bacterial respiratory illnesses, combined with heightened testing requirements following the COVID-19 pandemic, have significantly propelled the demand for respiratory disease-related microbiology testing.

Order a free sample PDF of the Clinical Microbiology Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2023 Market Size: USD 4.57 Billion

• 2030 Projected Market Size: USD 6.60 Billion

• CAGR (2024-2030): 5.35%

• North America: Largest market in 2023

Key Companies & Market Share Insights:

Product launches, regulatory approvals, strategic acquisitions, and continuous innovations are among the key business strategies that market participants have adopted to reinforce and expand their global presence. These approaches enable companies to enhance their product portfolios, enter new markets, and respond more effectively to evolving customer needs. Furthermore, such strategies help organizations maintain a competitive edge in a rapidly advancing clinical microbiology landscape.

Technological innovations—particularly the introduction of automated systems featuring advanced and efficient designs—are anticipated to further intensify competition among industry players. These next-generation systems enhance accuracy, reduce manual workload, and improve workflow efficiency, ultimately reshaping market dynamics. As companies continue to invest in innovation and automation, the competitive environment is expected to become more dynamic over the forecast period, driving ongoing advancements across the industry.

Key Players

• bioMerieux SA

• Abbott

• BD

• Danaher (Cepheid, Inc.)

• Hologic, Inc.

• F. Hoffmann-La Roche Ltd.

• Bruker

• Bio-Rad Laboratories, Inc.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The clinical microbiology market is poised for continued growth, driven by rising demand for diagnostic and surveillance services for infectious diseases, increasing global healthcare spending, and expanded use of advanced molecular and automated testing technologies. The growing burden of respiratory and other infectious diseases, along with heightened awareness of infection control and public health needs, fuels steady demand for reagents and laboratory instruments. Market growth is further supported by innovation in automated microbial identification, improved diagnostic speed and accuracy, and broader adoption across hospitals, diagnostic labs, and research centers.